These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 25746548)

  • 1. Relationship between beta-blocker and angiotensin-converting enzyme inhibitor dose and clinical outcome following acute myocardial infarction.
    Grall S; Biere L; Le Nezet M; Bouvier JM; Lucas-Chauvelon P; Richard C; Abi-Khalil W; Delepine S; Prunier F; Furber A
    Circ J; 2015; 79(3):632-40. PubMed ID: 25746548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of acute beta-blocker therapy on top of aspirin and angiotensin-converting enzyme inhibitor therapy in consecutive patients with ST-elevation acute myocardial infarction.
    Wienbergen H; Zeymer U; Gitt AK; Juenger C; Schiele R; Heer T; Towae F; Senges J;
    Am J Cardiol; 2007 May; 99(9):1208-11. PubMed ID: 17478143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to ACC/AHA performance measures for myocardial infarction in six Middle-Eastern countries: association with in-hospital mortality and clinical characteristics.
    Longenecker JC; Alfaddagh A; Zubaid M; Rashed W; Ridha M; Alenezi F; Alhamdan R; Akbar M; Bulbanat BY; Al-Suwaidi J
    Int J Cardiol; 2013 Aug; 167(4):1406-11. PubMed ID: 22578736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doses of renin-angiotensin system inhibitors but not beta-blockers predict outcome after ST-elevation myocardial infarction.
    Liu PY; Chen CL; Yu MC; Ko YL; Hsu SY; Chou HH; Yeh KH; Duan DM; Chen MH; Lin JF
    Acta Clin Belg; 2019 Oct; 74(5):334-341. PubMed ID: 30295167
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of renin-angiotensin system inhibitors on long-term survival in patients treated with beta blockers and antiplatelet agents after acute myocardial infarction (from the MONICA/KORA Myocardial Infarction Registry).
    Amann U; Kirchberger I; Heier M; Zirngibl A; von Scheidt W; Kuch B; Peters A; Meisinger C
    Am J Cardiol; 2014 Aug; 114(3):329-35. PubMed ID: 24927969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study.
    Krum H; Shi H; Pitt B; McMurray J; Swedberg K; van Veldhuisen DJ; Vincent J; Pocock S; Zannad F;
    Circ Heart Fail; 2013 Jul; 6(4):711-8. PubMed ID: 23625945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction.
    Arnold SV; Spertus JA; Masoudi FA; Daugherty SL; Maddox TM; Li Y; Dodson JA; Chan PS
    J Am Coll Cardiol; 2013 Nov; 62(19):1791-801. PubMed ID: 23973701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of combined beta-blocker and angiotensin-converting enzyme inhibitor treatment on 1-year survival after acute myocardial infarction: findings of the PRIAMHO-II registry].
    Arós F; Loma-Osorio A; Vila J; López-Bescós L; Cuñat J; Rodríguez E; San José JM; Heras M; Marrugat J;
    Rev Esp Cardiol; 2006 Apr; 59(4):313-20. PubMed ID: 16709383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Beta-Blocker Dose on Survival After Acute Myocardial Infarction.
    Goldberger JJ; Bonow RO; Cuffe M; Liu L; Rosenberg Y; Shah PK; Smith SC; Subačius H;
    J Am Coll Cardiol; 2015 Sep; 66(13):1431-41. PubMed ID: 26403339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suboptimal use of evidence-based medical therapy in patients with acute myocardial infarction from the Korea Acute Myocardial Infarction Registry: prescription rate, predictors, and prognostic value.
    Lee JH; Yang DH; Park HS; Cho Y; Jeong MH; Kim YJ; Kim KS; Hur SH; Seong IW; Hong TJ; Cho MC; Kim CJ; Jun JE; Park WH; Chae SC;
    Am Heart J; 2010 Jun; 159(6):1012-9. PubMed ID: 20569714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
    Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
    Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF Registry.
    Peri-Okonny PA; Mi X; Khariton Y; Patel KK; Thomas L; Fonarow GC; Sharma PP; Duffy CI; Albert NM; Butler J; Hernandez AF; McCague K; Williams FB; DeVore AD; Patterson JH; Spertus JA
    JACC Heart Fail; 2019 Apr; 7(4):350-358. PubMed ID: 30738978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy after hospital discharge on subsequent rehospitalization for acute myocardial infarction and heart failure.
    Hess G; Preblick R; Hill J; Plauschinat CA; Yaskin J
    Congest Heart Fail; 2009; 15(4):170-5. PubMed ID: 19627290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in adherence to evidence-based medications in the first year after initial hospitalization for heart failure: observational cohort study from 1994 to 2003.
    Lamb DA; Eurich DT; McAlister FA; Tsuyuki RT; Semchuk WM; Wilson TW; Blackburn DF
    Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):228-35. PubMed ID: 20031842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of 5-year survival after acute myocardial infarction using angiotensin-converting enzyme inhibitor versus angiotensin II receptor blocker.
    Hara M; Sakata Y; Nakatani D; Suna S; Usami M; Matsumoto S; Sugitani T; Nishino M; Sato H; Kitamura T; Nanto S; Hamasaki T; Hori M; Komuro I;
    Am J Cardiol; 2014 Jul; 114(1):1-8. PubMed ID: 24819900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of use and potential impact of early beta-blocker therapy in non-ST-elevation myocardial infarction with and without heart failure: the Global Registry of Acute Coronary Events.
    Emery M; López-Sendón J; Steg PG; Anderson FA; Dabbous OH; Scheuble A; Eagle KA;
    Am Heart J; 2006 Dec; 152(6):1015-21. PubMed ID: 17161045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Angiotensin-converting enzyme inhibition on one-year mortality and frequency of repeat acute myocardial infarction in patients with acute myocardial infarction.
    Milonas C; Jernberg T; Lindbäck J; Agewall S; Wallentin L; Stenestrand U;
    Am J Cardiol; 2010 May; 105(9):1229-34. PubMed ID: 20403471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond β-Blockade: ACE Inhibitors Reduce Non-Cardiac Mortality in High Killip Grade AMI Patients.
    Sun S; Han X; Bai L; Jeong MH; Jin C
    J Cardiovasc Pharmacol Ther; 2024; 29():10742484241264673. PubMed ID: 39033435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of adding aspirin to beta-blocker and statin in high-risk patients undergoing major vascular surgery.
    Lau WC; Froehlich JB; Jewell ES; Montgomery DG; Eng KM; Shields TA; Henke PK; Eagle KA
    Ann Vasc Surg; 2013 May; 27(4):537-45. PubMed ID: 23535525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [ACE inhibitors and angiotensin II receptor antagonists in acute coronary syndrome].
    Milicić D
    Acta Med Croatica; 2004; 58(2):129-34. PubMed ID: 15208798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.